# Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients

> **NCT01202591** · PHASE1,PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 127 (actual)

## Conditions studied

- FGFR Inhibition, Pharmacokinetics, Biomarkers
- ER+ Breast Cancer

## Interventions

- **DRUG:** AZD4547
- **DRUG:** Exemestane
- **DRUG:** Placebo
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT01202591
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2014-09
- **Final completion:** 2014-10
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2016-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01202591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01202591, "Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT01202591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*